DRMA

Dermata Therapeutics, Inc. (DRMA) Business Model Analysis (2026)

Invetso Score: 4.9/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Value Proposition Revenue Model

Score: 4.8 (Moderate)

Revenue mix: The provided metrics do not show a diversified revenue mix, limiting visibility into how DRMA captures value across products or services.

Capital-light profile: Near-zero capex intensity suggests a light asset base, which can support margins but does not by itself indicate a stronger revenue model than peers.

R&D intensity: Reported R&D-to-revenue is zero in the supplied data, implying limited disclosed reinvestment intensity and reducing evidence of a structurally differentiated offering.

Cost Structure

Score:

Low capital intensity: Capex-to-revenue at zero indicates low maintenance investment needs, which can support operating flexibility and lower fixed-cost burden.

Cash conversion: Income quality of 0.96 indicates earnings convert to cash reasonably well, supporting a cleaner cost structure than more working-capital-intensive peers.

Disclosure limits: The supplied metrics do not quantify labor, manufacturing, or SG&A leverage, so structural cost advantages versus peers remain only partially visible.

Scalability Operating Leverage

Score:

Asset-light scaling: Zero capex intensity suggests incremental revenue may require limited reinvestment, but the absence of asset-turnover data prevents confirming strong operating leverage.

Limited reinvestment signal: Zero reported R&D intensity weakens evidence that growth can scale through repeatable product development or platform economics.

Peer comparison: Compared with higher-intensity peers, DRMA appears less capital-hungry, but the available data do not prove superior scalability.

Customer Structure Concentration

Score:

Customer visibility: No customer concentration metrics were provided, so the business model’s dependence on a small number of buyers cannot be assessed from the supplied data.

Predictability implication: Limited disclosure on end-market or customer mix reduces confidence that revenue is structurally diversified versus peers.

Structural constraint: Without concentration data, the model cannot be credited for resilience, and hidden customer dependence remains a potential drag on quality.

Revenue Quality Predictability

Score:

Cash conversion: Income quality of 0.96 indicates reported earnings are backed by cash flow, which supports revenue quality and reduces accounting noise.

Free cash flow visibility: FCF margin was not provided, limiting assessment of how consistently revenue converts into durable owner earnings.

Predictability versus peers: The available metrics suggest acceptable quality, but not enough recurring-revenue evidence to rank DRMA above structurally steadier peers.

Overall Score

Score:

DRMA appears structurally moderate, with a light capital base and decent cash conversion offset by limited visibility into revenue mix, customer concentration, and scalable reinvestment.

Score Driver: The Dominant Positive Is Low Capital Intensity, While The Main Limitation Is Insufficient Evidence Of Durable, Diversified, And Repeatable Revenue Generation.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Dermata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →